Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study by Donovan, K, Herrington, W, Haynes, R, Sardell, R, Baigent, C, Holmes, M, Staplin, N

Determinants of post-operative atrial fibrillation in 1613 patients undergoing coronary artery bypass grafting in the statin therapy in cardiac surgery (stics) trial by Wijesurendra, R, Sardell, R, Hill, M, Jayaram, R, Staplin, N, Collins, R, Chen, Z, Emberson, J, Haynes, R, Casadei, B

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial by Mayne, K, Sardell, R, Staplin, N, Judge, P, Zhu, D, Sammons, E, Emberson, J, Preiss, D, Landray, M, Baigent, C, Haynes, R, Herrington, W

Mechanisms of acute kidney injury with perioperative rosuvastatin in patients undergoing cardiac surgery by Wijesurendra, RS, Sardell, R, Jayaram, R, Samuel, N, Chen, Z, Staplin, N, Collins, R, Zheng, Z, Haynes, R, Hill, M, Emberson, J, Casadei, B

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial by Mayne, KM, Sardell, R, Staplin, N, Judge, P, Zhu, D, Sammons, E, Wanner, C, Emberson, J, Preiss, D, Landray, M, Baigent, C, Haynes, R, Herrington, W

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial by Judge, PK, Tuttle, KR, Staplin, N, Hauske, SJ, Zhu, D, Sardell, R, Cronin, L, Green, JB, Agrawal, N, Arimoto, R, Mayne, KJ, Sammons, E, Brueckmann, M, Shah, SV, Rossing, P, Nangaku, M, Landray, MJ, Wanner, C, Baigent, C, Haynes, R, Herrington, WG